Post-earnings recap
Reported
Tue, May 5, 2026
EPS actual
$-2.28
EPS est.
$-2.52
EPS surprise
+9.45%
1-day move
-3.88%
BioNTech reported a larger-than-expected loss per share, which contributed to a 3.88% decline in its stock price. The company did not provide revenue figures or guidance, leaving investors uncertain about future performance. The stock reaction indicates investor concern over the missed EPS and lack of clarity on revenue expectations.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-2.28 | $-1.91 | +9.45% |
| Revenue | — | $159M | — |
No transcript is on record, and the analysis is based solely on numerical results.
BioNTech SE is a biotechnology company focused on developing and manufacturing immunotherapies for cancer and infectious diseases. As a key player in the healthcare sector, it gained significant attention for its COVID-19 vaccine, and its ongoing research may impact future treatments and vaccine developments.
Last quarter
In the last quarter, BioNTech reported a larger-than-expected loss, which disappointed investors and led to a significant drop in stock price. The company did not provide specific guidance, leaving analysts uncertain about future performance.
EPS beat streak
2Q
EPS beat rate
75%
Avg EPS surprise
+18.51%
Avg 1-day reaction
-3.66%
Analysts are expecting a continued struggle for BioNTech, with losses projected to widen compared to previous quarters. Revenue expectations are modest, reflecting concerns about the company's post-COVID vaccine market position.
Bull case
If BioNTech can demonstrate strong revenue growth and better-than-expected cost management, it could signal a recovery and renewed investor confidence in its pipeline.
Bear case
Conversely, if the company reports wider losses and lower revenue, it may indicate deeper issues with its product pipeline and market strategy, leading to further stock declines.
Key metrics to watch
EPS
$-1.91Earnings per share is a critical measure of profitability, and a significant loss is expected this quarter.
Revenue
$159MRevenue figures will indicate the company's ability to generate income, especially as it navigates post-pandemic challenges.
The print will turn on these.
Q1
Will BioNTech's revenue exceed the consensus estimate of $159M?
Revenue performance is crucial for assessing the company's recovery trajectory and market demand for its products.
Q2
How will management address the expected EPS loss of $-1.91?
Understanding the reasons behind the anticipated losses will provide insights into the company's operational efficiency and future strategy.
—
Est. EPS
$0.01
Est. Rev
$918M
Impl. Move
±9.1%
Why consensus could be wrong
The Street may underestimate BioNTech's potential for revenue recovery due to its ongoing research and development efforts that could yield new products.
Supporting evidence
Despite recent losses, BioNTech's pipeline includes promising therapies that could drive future growth.
The options market indicates a significant expected move, suggesting that investors are anticipating a more dynamic outcome than the consensus reflects.
Key risk
If revenue comes in below $159M, it could signal deeper issues in BioNTech's market strategy.
Pre-commit to what would confirm each case.
The market is debating BioNTech's ability to recover from recent losses and its future revenue potential.
Bull confirmed if
Revenue exceeding $159M with a narrower EPS loss than expected would confirm the bull case.
Bear confirmed if
An EPS loss greater than $-1.91 and revenue below $159M would reinforce the bear case.
What the market is pricing for the move.
Implied Move
±5.9%
Historical Avg
±4.3%
The options market is pricing in a nearly 6% move, suggesting that investors expect significant volatility around the earnings announcement.
Options are pricing ±6.2% while BNTX has averaged ±4.3% over the last 8 prints — setup is pricing rich.
ATM IV
0.6%
30d HV
39.5%
Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.
Bought
$0.00
0 sh
0 insiders
Sold
$27.1M
278,000 sh
1 insider
Net
$27.1M
Net selling
Most Active Insiders· 9 open-market trades
$27.1M
Net selling
Smart-money positioning from the most recent 13F filings.
Institutional
20.45%
of float
Insider
57.24%
of float
Holders
476
institutions
Top Holders· as of Jun 2026
FMR, LLC
7,571,805 sh · $721.2M
2.99%
32.6%
Likely market behavior by outcome. Not investment advice.
Beat & raise
If BioNTech beats expectations, history suggests a potential stock increase of around 2.5%, confirming a positive outlook.
In line / cautious
An in-line report may lead to muted reactions as the market assesses management's commentary on future prospects.
Miss
If the company misses expectations, the stock could drop by about 5.4%, indicating ongoing concerns about its financial health.
The lines on the call that would change the story.
Recent Transactions
Oct 5, 2026 · @ $97.23
72,000 sh
$7.0M
Sep 28, 2026 · @ $98.47
34,000 sh
$3.3M
Sep 29, 2026 · @ $98.26
34,000 sh
$3.3M
Sep 30, 2026 · @ $98.12
32,000 sh
$3.1M
Sep 25, 2026 · @ $98.69
27,000 sh
$2.7M
Open-market trades only (Form 4 codes P/S). Awards, exercises, and tax-withholding excluded as routine compensation noise.
Primecap Management Company
3,772,031 sh · $359.3M
1.49%
-0.6%
Dodge & Cox Inc.
3,677,591 sh · $350.3M
1.45%
0.0%
Flossbach von Storch SE
2,226,138 sh · $212.0M
0.88%
-39.5%
T. Rowe Price Investment Management, Inc.
2,065,456 sh · $196.7M
0.82%
-64.7%
13F filings updated quarterly. Position deltas show change in shares vs. the prior quarter.